同时性结直肠癌肝转移患者行结直肠癌切除联合射频消融治疗的临床整体疗效研究

目的研究分析结直肠癌切除联合射频消融治疗同时性结直肠癌肝转移患者的整体临床疗效。方法本研究回顾性分析2013年1月至2016年1月本院收治的同时性结直肠癌肝转移患者45例。其中21例患者行结直肠癌切除联合射频消融治疗,另外24例患者行周期病灶手术切除治疗。观察两组患者手术时间、术中出血量、术中输血例数、住院时间、术后并发症等情况。结果 A组的术中出血量、术中输血例数、住院时间均少于B组(P0.05);A组患者术后化疗行FOLFOX方案者4例,FOLFIRI方案者3例,XELOX方案者9例;B组患者术后化疗行FOLFOX方案者5例,FOLFIRI方案者5例,XELOX方案者7例。A组患者术后1年的死亡率为38.09%(8例),B组患者术后1年的死亡率为37.50%(9例),两组患者术后1年死亡率无显著差异(P0.05)。结论对于同时性结直肠癌肝转移采用结直肠癌切除联合射频消融治疗,可以在一定程度上较少手术治疗过程的出血量及输血例数,缩短病人住院时间,与手术切除治疗组在术后1年的死亡率无明显差异,因此结直肠癌切除联合射频消融可作为同时性结直肠癌肝转移治疗备用方案,特别适用于无法行切除的肝转移病灶患者。     

腹腔镜与开腹二期肝切除治疗结直肠癌肝转移的短期疗效比较

【摘要】 目的 探讨腹腔镜肝切除与开腹肝切除对结直肠癌肝转移的短期疗效。方法 自2008年1月至2012年12月,对94例结直肠癌肝转移患者行二期肝切除,其中腹腔镜手术46例,开腹手术48例,收集并比较两组患者的短期疗效资料。所有患者中,左半肝切除35例,右半肝切除28例,不规则楔形切除术31例;原发结直肠癌切除后3~6个月再次采取手术进行肝内病灶切除。 结果 腹腔镜肝切除的结直肠癌肝转移患者术中出血量较开腹组明显减少(P<0.05),住院时间显著缩短(P<0.05),且具有较低的术后谷丙转氨酶、谷草转氨酶、胆红素及白细胞水平(P<0.05)。两组并发症发生率差异无统计学意义。 结论 对于结直肠癌肝转移二期肝切除患者,腹腔镜手术安全可靠,术后短期疗效较开腹好。     

结直肠癌同时性肝转移治疗46例分析

目的:探讨结直肠癌同时性肝转移的有效治疗方法。方法:对1996～2004年收治的46例结直肠癌同时性肝转移的临床资料和随访资料进行回顾性分析。根据治疗方法的不同分为3组:A组21例,为一期切除原发灶和肝转移灶并经肝动脉和门静脉置泵化疗者;B组15例,为单纯原发灶切除并经肝动脉和门静脉置泵化疗者;C组10例,为原发灶和肝转移灶均未能切除而仅行肝动脉和门静脉置泵化疗者。用KaplanMeier法对病人的生存时间作统计分析。结果:A、B、C3组术后中位生存期分别为38、20和13个月;各组之间术后生存时间的比较均有显著统计学差异(P<0.01)。结论:结直肠癌原发灶和肝转移灶一期手术切除并经肝动脉和门静脉置泵化疗的疗效最好;肝转移灶无法切除者能将原发灶切除并经肝动脉和门静脉置泵化疗也可取得较好的疗效;原发灶和肝转移灶未能切除而仅经肝动脉和门静脉置泵化疗的疗效相对较差。对结直肠癌同时性肝转移应采取以手术切除为主的综合措施进行积极治疗。     

腹腔镜结直肠癌肝转移Ⅰ期切除术疗效观察

目的探讨腹腔镜结直肠癌肝转移Ⅰ期切除术的疗效。方法将35例结直肠癌并肝转移的患者按照不同手术方法分为2组,治疗组(16例)行腹腔镜Ⅰ期联合切除术,对照组(19例)行传统开腹Ⅰ期切除术。术后患者均定期全身化疗。结果 2组患者均顺利完成手术。2组手术时间及住院时间比较,差异无统计学意义(P0.05)。治疗组术中出血量少于开腹组,并发症发生率低于对照组,2组差异均有统计学意义(P0.05)。术后随访6个月,均无死亡病例。结论对结直肠癌肝转移患者实施腹腔镜和开腹Ⅰ期联合切除手术疗效相近。但腹腔镜手术创伤小、手术并发症少,效果肯定。     

腹腔镜联合开腹同期切除结直肠癌伴肝转移的可行性分析

目的探讨腹腔镜联合开腹同期切除手术方式在治疗结直肠癌伴肝转移的临床价值。方法选取2009年1月至2012年12月我院34例术前确诊为结直肠癌伴肝转移患者,其中19例行腹腔镜联合开腹同期切除结直肠癌及肝转移病灶作为治疗组,15例行传统开腹同期切除为对照组,观察两组近期疗效,对手术时间、术中出血量、术后首次排气时间以及术后并发症进行对比分析。结果 19例治疗组患者手术时间为(97±2)min,术中出血量为(106±2)mL,术后首次排气的时间为(2.65±1.58)d,住院时间为(11.26±1.89)d,均优于对照组患者(P<0.05)。治疗组的并发症发生率为10.53%,明显低于对照组的33.33%(P<0.05)。结论同期腹腔镜联合开腹手术治疗结直肠癌及肝转移是安全有效的,且术后恢复快,住院时间短,并发症发生率低,较传统开腹手术更加安全可靠,能为部分结直肠癌晚期患者的治疗提供了较好的选择方案。     

腹腔镜下结直肠癌肝转移一期手术23例临床疗效

目的探讨腹腔镜下治疗结直肠癌肝转移一期的安全性及有效性。方法回顾分析2011年1月至2013年6月行结直肠癌肝转移手术的43例患者的临床资料,将23例患者同时行腹腔镜切除肝转移灶切除术纳入腹腔镜组,20例患者同时行开放性肝转移灶切除术患者纳入开腹组。采用SPSS 23.0软件进行分析,中位生存时间、生存率及术后并发症比较采用χ2检验;计量资料采用(x珋±s)表示,比较采用独立样本t检验,生存分析采用Kaplain-Meire法计算生存率。P0.05表示差异有统计学意义。结果腹腔镜组患者手术时间及术后腹腔引流管留置时间较开腹组显著减少(P0.05);两组患者术中出血量、术后肛门排气时间及术后住院时间差异无统计学意义(P0.05);两组患者术后生存率相近,无围手术期死亡病例,术后均未见严重术后并发症。结论腹腔镜下结直肠癌肝转移一期联合切除安全可行,具有较好的疗效。     

个体化治疗直肠癌同时性肝转移

肝转移是影响结直肠癌预后的重要因素之一。一般认为手术切除是唯一可能治愈结直肠癌肝转移的治疗手段。而近年随着新辅助化疗与肿瘤物理消融技术以及微创技术的进展,尤其在生物一心理一社会的现代医学模式背景下,对可以手术切除的结直肠癌同时性肝转移患者如何选择更为合理的手术方式尚存在较多争议。中国医科大学附属盛京医院收治1例直肠癌同时性肝转移患者经新辅助化疗后腹腔镜下肝转移癌微波消融＋开腹结直肠癌根治性切除术的联合序贯治疗,为同类患者治疗方式的个体化选择提供参考。     

结直肠癌肝转移的腹腔镜微创治疗

目的:探讨腹腔镜手术治疗结直肠癌肝转移的临床疗效。方法:回顾分析2008~2014年收治的62例结直肠癌并肝转移患者的临床资料,其中15例行腹腔镜切除结直肠癌同期行肝转移癌切除(手术组),47例患者采用腹腔镜切除结直肠癌同期行肝转移癌射频消融(radio frequency ablation,RFA)。结果:手术组手术时间平均(4.6±1.1)h,术中出血量平均(610±275)ml。RFA组手术时间平均(4.1±1.3)h,术中出血量平均(410±115)ml。两组3个月肝转移癌复发率相近,约1/3,手术组1年、3年、5年生存率分别为53%、50%、50%,RFA组分别为49%、48%、45%。结论:腹腔镜结直肠癌切除同期行肝转移癌切除及射频消融术患者创伤小、康复快,手术安全、有效,可避免二期手术的创伤,延长结直肠癌晚期患者的生存时间。     

结直肠癌同时肝转移和腹膜转移的处理及预后

目的 探讨结直肠癌同时性肝转移和腹膜扩散患者的相关临床病理因素以及手术干预对其预后的影响.方法 回顾性分析12年间中山大学附属第一医院肠癌数据库资料中有同时性肝转移和/或腹膜扩散患者(166例/150例)的临床病例资料及随访结果.结果 在诸多病理因素中肿瘤分化程度和浆膜浸润与腹膜扩散有关(P<0.01),而肿瘤分化程度,浆膜浸润和Ducks分期等与同时性肝转移有关(P<0.01);手术不可切除的结直肠癌伴同时性肝转移组与伴腹膜扩散组的短期和长期生存率差异无统计学意义(P>0.05),而在手术可切除组中伴腹膜扩散者的长期生存率优于伴肝转移者(P<0.01).结论 结直肠癌腹膜转移患者较同时性肝转移患者长期顶后好;手术不可切除的结直肠癌伴腹膜扩散或肝转移才标示着肿瘤的终末期;结直肠癌伴腹膜转移根治切除组较伴同时性肝转移根治切除组预后好,局限的结直肠癌伴腹膜转移通过手术可能得到根治.     

腹腔镜结直肠癌根治术与传统根治术的临床效果对比

目的:对比腹腔镜结直肠癌根治术与传统开腹手术的临床疗效,评价腹腔镜结直肠癌根治术的可行性、安全性及有效性。方法:选择2011年4月至2015年4月接受治疗的49例结直肠癌患者作为研究对象,其中27例行腹腔镜手术(腹腔镜组),22例行传统开腹手术(开腹组)。对比两组患者手术时间、术中出血量、术后胃肠功能恢复时间、住院时间、复发情况。结果:腹腔镜组术中出血量、手术时间、术后自主排气时间、进食时间及住院时间优于开腹组,差异有统计学意义(P<0.05);腹腔镜组术后生存质量评分显著优于开腹组(P<0.05)。结论:熟悉腹腔镜手术的操作技巧,严格掌握手术适应证,腹腔镜辅助结直肠癌手术是安全、可靠的,疗效确切,患者创伤小,术中出血量少,手术时间短,术后康复快,可作为首选术式。     

腹腔镜下结直肠癌合并肝转移癌一期同时切除术的临床分析

目的探究腹腔镜下结直肠癌合并肝转移癌一期同时切除术的安全性及可行性。方法选取68例2012年11月~2015年6月至我院以及中山大学孙逸仙纪念医院胃肠外科二区就诊的结直肠癌合并肝转移癌患者,将所有患者分为两组,观察组34例,对照组34例。观察组采取腹腔镜下结直肠癌合并肝转移癌同期切除术,对照组采取传统的开腹结直肠癌合并肝转移癌同期切除术。记录两组患者术中出血量、手术时间、术后排气时间、总住院时间、术后并发症,对两组疗效、总生存期和无瘤生存期进行分析。结果观察组术中出血量、手术时间、术后排气时间、总住院时间与对照组相比,有统计学意义(P0.05);虽然观察组的术并发症比对照组低,但两组术后并发症比较无统计学意义(P0.05)。结论全腹腔镜下结直肠癌合并肝转移癌一期联合切除安全可行,总体临床效果优于开腹手术。     

完全腹腔镜治疗结肠癌伴同时性肝转移的临床疗效

目的：探讨腹腔镜下行结肠癌根治术与肝转移灶切除术的安全性及疗效。 方法：选择2009年3月―2011年4月收治的50例结肠癌同时性肝转移患者,其中25例患者行腹腔镜下结肠癌根治术及肝转移灶切除术（腹腔镜组）,另25例在传统开腹手术（开腹组）。比较两组患者的术中情况、术后恢复情况以及术后1、2、3年生存率。 结果：腹腔镜组的术中出血量、术后镇痛时间、排气时间、住院时间及并发症均明显少于开腹组（P<0.05）,但两组的手术时间差异无统计学意义（P>0.05）。两组患者术后1、2、3年生存率差异无统计学意义（均P>0.05）。 结论：完全腹腔镜治疗结肠癌伴同时性肝转移安全可行,与开腹手术疗效相同,同时具有创伤小、术后恢复快、并发症少等优点。     

腹腔镜联合辅助化疗及内镜治疗进展期结直肠癌合并腺瘤的应用研究

目的：探讨腹腔镜结直肠癌切除术加辅助化疗加二期内镜下治疗结直肠癌合并根治术切除范围外结直肠腺瘤的临床应用价值。方法：2005年1月-2010年6月对54例进展期结直肠癌合并根治术切除范围外结直肠腺瘤（〉1．0cm）的患者（研究组）行腹腔镜结直肠癌切除术加辅助化疗（FOLFOX4方案）加二期内镜下腺瘤切除的综合治疗,对同期396例单发进展期结直肠癌患者（对照组）行腹腔镜结直肠癌切除术加辅助化疗（FOLFOX4方案）。通过并发症发生率、长期随访等评价治疗效果。结果：2组患者在年龄、性别、手术方式、手术时间、术中出血量、并发症发生率、平均住院时间、肿瘤大小、淋巴结转移、TNM分期及1、3和5年存活率差异无统计学意义（P〉O．05）。研究组辅助化疗后对合并腺瘤进行内镜下切除治疗,4例出血经保守治疗后成功止血,未发生穿孔、狭窄等严重并发症;3例患者术后病理组织学检查为腺瘤癌变,其中2例癌变局限于腺瘤中,1例癌细胞侵犯达黏膜下层,该例患者再次行腹腔镜下切除,术后随访无复发。结论：腹腔镜联合辅助化疗及内镜为合并结直肠癌根治术切除范围外腺瘤的患者提供了一种安全有效的微创治疗方法,值得临床推厂和应用。     

Totally laparoscopic strategies for the management of colorectal cancer with synchronous liver metastasis

Introduction

Laparoscopy is an accepted treatment for colorectal cancer and liver metastases, but there is no consensus for its use in the management of synchronous liver metastases (SCRLM). The purpose of this study was to evaluate totally laparoscopic strategies in the management of colorectal cancer with synchronous liver metastases.

Methods

Patients presenting to Ninewells Hospital between July 2007 and August 2010, with adenocarcinoma of the colon and rectum with synchronous liver metastases were considered. Patients underwent simultaneous laparoscopic liver and colon cancer resection, a staged laparoscopic resection of SCRLM and colon cancer, or simultaneous colon resection and radiofrequency ablation (RFA) of SCRLM. Primary endpoints were in-hospital morbidity and mortality, total hospital stay, intraoperative blood loss, duration of surgery, and resection margin status.

Results

Twenty-eight patients presented with synchronous colorectal liver metastases. Thirteen patients underwent a simultaneous laparoscopic liver and colon resection (median operating time, 370 (range, 190–540) min; median hospital stay, 7 (range, 3–54) days), seven patients had a staged laparoscopic resection of SCRLM and primary colon cancer (median operating time, 530 (range, 360–980) min; median hospital stay 14, (range, 6–51) days), and eight patients underwent laparoscopic colon resection and RFA of SCRLM (median operating time, 310 (range, 240–425) min; median hospital stay, 8 (range, 6–13) days). There were no conversions to an open procedure. Overall in-hospital morbidity and mortality was 28 and 0?% respectively. An R0 resection margin was achieved in 91?% of the resection group. At a median follow-up of 26 (range, 18–55) months, 19 (90?%) patients remain disease-free.

Conclusions

Totally laparoscopic strategies for the radical treatment of stage IV colorectal cancer are feasible with low morbidity and favorable outcomes. A laparoscopic approach for the simultaneous management of SCRLM and primary colon cancer is associated with reduced surgical access trauma, postoperative morbidity, and hospital stay with no compromise in short-term oncological outcome.     

Simultaneous resection of colorectal cancer and liver metastases in the right lobe using pure laparoscopic surgery

It is now common to resect colorectal cancer by laparoscopic surgery. Hepatectomy has become a standard treatment for patients with colorectal cancer with resectable liver metastases. The resection of liver tumors can now be done partly by laparoscopic surgery. However, metastatic tumors in the right lobe are often difficult to resect laparoscopically. Furthermore, simultaneous resection of the colorectum and liver may also be difficult. In this study, we evaluated a new method to resect both colorectal cancer and liver metastases in the right lobe by laparoscopic surgery. Two cases are presented that underwent total laparoscopic resection of a right lobe tumor, associated with laparoscopic colorectal resection. The metastatic tumor in the right lobe was first resected in the left hemi-prone position. Then, the colorectal cancer was resected in the lithotomy position. The method for resecting the right lobe liver tumor and colorectal cancer was safe and feasible. The mean duration of surgery was 443.5 min, and the mean blood loss was 158 mL. The postoperative course was uneventful. In selected patients, laparoscopic hepatectomy for right lobe synchronous metastatic tumors can be safely performed simultaneously with colorectal surgery.     

腹腔镜下结直肠癌肝转移同时根治切除的临床研究

目的研究腹腔镜结直肠癌根治性切除联合腹腔镜切除治疗结直肠癌肝转移的临床疗效。 方法回顾性分析2014年1月至2015年12月确诊为同时性结直肠癌肝转移患者90例资料。分为腹腔镜组(n＝45)和开腹组(n＝45),采用SPSS21.0统计软进行数据分析,术中术后指标采用( ±s)表示,独立t检验;术后并发症采用χ²检验;偏态分布的资料采用M(Qn)和M(范围)表示,应用Mann－Whitney U检验。P<0.05为差异有统计学意义。 结果两组患者手术时间、术中出血量、术中输血量、神经浸润及脉管侵犯等差异无统计学意义(P>0.05)。术后情况：两组患者在进食时间、术后TBIL、术后ALT、并发症及住院时间差异无统计学意义(P>0.05);而腹腔镜组入住ICU的患者时间为(2.1±1.6) d,明显短于开腹组(1.0±06) d (t＝1.804, P<0.05)。随访结果：两组术后1、2年累积无瘤生存率和生存时间差异无统计学意义(P>0.05)。 结论腹腔镜结直肠癌根治性切除术联合腹腔镜肝切除术在安全性优于腹腔镜结直肠癌根治性切除治疗联合开腹肝切除术,但两种治疗方法在术后并发症发生率及临床预后等方面效果相当。     

腹腔镜下结直肠癌根治术中联合腹腔热灌注化疗的临床研究

目的:探讨腹腔镜下结直肠癌根治术中联合腹腔热灌注化疗(IHPC)的安全性及可行性。方法:将120例进展期结直肠癌患者随机分成治疗组和对照组,每组各60例。两组患者均接受腹腔镜下结直肠癌根治术,治疗组术中行IHPC联合术后m FOLFOX6方案静脉化疗;对照组单纯行术后m FOLFOX6方案静脉化疗。比较两组患者手术相关指标、术后恢复情况、术后并发症、不良反应、局部复发率及远处转移率。结果:两组患者在手术相关指标、术后恢复情况、术后并发症方面差异均无统计学意义(均P>0.05);治疗组术后低蛋白血症和低钠血症的发生率明显高于对照组(20.0%vs.6.7%;15.0%vs.3.3%,均P<0.05);腹腔局部复发率和远处转移率明显低于对照组(6.7%vs.18.3%;8.3%vs.23.3%,均P<0.05);两组短期总生存率相当(P>0.05)。结论:腹腔镜下结直肠癌根治术中IHPC联合术后静脉化疗安全可靠,对局部复发及远处转移疗效较好。     

Short-Term Outcomes of Simultaneous Laparoscopic Colectomy and Hepatectomy for Primary Colorectal Cancer With Synchronous Liver Metastases

Although simultaneous resection of primary colorectal cancer and synchronous liver metastases is reported to be safe and effective, the feasibility of a laparoscopic approach remains controversial. This study evaluated the safety, feasibility, and short-term outcomes of simultaneous laparoscopic surgery for primary colorectal cancer with synchronous liver metastases. From September 2008 to December 2013, 10 patients underwent simultaneous laparoscopic resection of primary colorectal cancer and synchronous liver metastases with curative intent at our institute. The median operative time was 452 minutes, and the median estimated blood loss was 245 mL. Median times to discharge from the hospital and adjuvant chemotherapy were 13.5 and 44 postoperative days, respectively. Negative resection margins were achieved in all cases, with no postoperative mortality or major morbidity. Simultaneous laparoscopic colectomy and hepatectomy for primary colorectal cancer with synchronous liver metastases appears feasible with low morbidity and favorable outcomes.Key words: Simultaneous laparoscopic hepatectomy and colectomy, Primary colorectal cancer with synchronous liver metastases, Short-term outcomeColorectal cancer (CRC) is a leading cause of cancer-related death globally, and 14.5% of CRC patients have synchronous liver metastases that are identified during the diagnostic workup or during the course of treatment.¹ Surgical resection of the primary CRC and synchronous colorectal liver metastases (SCRLM) is warranted because this strategy offers the most effective therapy and is potentially curative. However, the optimal treatment schedule and strategy for treating CRC with SCRLM with surgery and chemotherapy remains unclear. Several reports have shown the benefit of simultaneous open resection of primary CRC and SCRLM versus a staged approach.²⁻⁴ In addition, recent improvements in laparoscopic surgery for CRC and liver cancer make this option attractive, and there are several reports of simultaneous laparoscopic colectomy and hepatectomy in the literature.⁵⁻¹⁴ In spite of these promising developments, though, the feasibility of these procedures has been controversial in terms of efficacy, safety, and outcome. The aim of this study was to evaluate the short-term operative and oncologic outcomes of simultaneous laparoscopic colectomy and hepatectomy for patients with primary CRC and SCRLM.     

Additive Chemotherapie bei Lebermalignomen zur Verbesserung der Operabilität

Complete tumor resection is the only curative option for patients with colorectal liver metastases. Hepatic resection is frequently not possible for technical reasons: because of large tumors, multiple or bilateral metastases, or tumors that are too close to vessels. In these cases chemotherapy might downstage the tumor volume and facilitate secondary curative resection in patients initially not eligible for curative surgery. Treatment with fluorouracil (5-Fu) alone has resulted in disappointing response rates of about 10-20% in patients with colorectal liver metastases, which make these protocols useless in the neoadjuvant setting. Because regional chemotherapy into the hepatic arteria results in significantly higher response rates (40-50%), some studies have documented some success in secondary curative surgery after regional chemotherapy of initially unresectable colorectal liver metastases. However, regional chemotherapy is invasive and therefore not standard therapy for every patient with colorectal liver metastases. Recently new exciting treatment options have become available for colorectal cancer. Combinations of chemotherapy consisting of irinotecan and 5-Fu/FA or oxaliplatin and 5-Fu/FA result in response rates of 50% and can be considered a new standard first-line chemotherapy for patients with metastatic colorectal cancer. Recently, two encouraging retrospective studies have been published with chronomodulated chemotherapy of oxaliplatin and 5-Fu/FA in the setting of neoadjuvant chemotherapy for patients with unresectable colorectal liver metastases. With this multidisciplinary approach, antitumor activity of chemotherapy appears to be translated into a long-term survival benefit and some patients with initially unresectable colorectal liver metastases can potentially be cured. As a consequence, on the premises of close cooperation between surgeons and internists, more patients with metastatic colorectal cancer will be cured in the future.